Related Experiment Video

Updated: May 2, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K

BRAF-mutations in non-small cell lung cancer

Odd Terje Brustugun1, Asma Malik Khattak2, Anette Kjoshagen Trømborg2

  • 1Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Lung Cancer (Amsterdam, Netherlands)
|February 21, 2014
PubMed
Abstract

Insights

BRAF-mutation testing is crucial for non-small cell lung cancer (NSCLC) patients, revealing a 1.7% mutation frequency. This analysis aids in identifying patients who may benefit from targeted therapies.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genetics

Background:

  • Targeted therapies for non-small cell lung cancer (NSCLC) now include BRAF inhibitors.
  • Identifying BRAF mutations is essential for patient stratification and treatment selection.

Purpose of the Study:

  • To determine the clinicopathological characteristics of BRAF V600E/K mutations in a large cohort of unselected NSCLC patients.
  • To assess the frequency and clinical relevance of BRAF mutations in NSCLC.

Main Methods:

  • Analysis of 979 unselected NSCLC patients tested for EGFR mutations.
  • BRAF V600E/K mutations were detected using a PCR-based method.
  • Data collected from Oslo University Hospital between February 2011 and July 2013.

Main Results:

  • A BRAF mutation frequency of 1.7% was observed in the total NSCLC cohort (979 patients).
  • The frequency was higher in adenocarcinomas (2.3% of 646 patients) and absent in squamous cell carcinomas (0% of 231 patients).
  • Notably, 29% of BRAF-positive patients were never-smokers, and co-mutations (KRAS, ALK) were rare.

Conclusions:

  • BRAF mutation analysis should be integrated into the routine subtyping of non-squamous NSCLC.
  • This testing can identify a subset of NSCLC patients eligible for BRAF-targeted therapies.
  • Findings support the clinical utility of BRAF mutation testing in NSCLC management.
Keywords:
BRAF-mutationEGFR-mutationGenetic testingLung cancerTyrosine kinase inhibitors

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

559

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K